JP-WXDC@EC2611A

7ROAD

NEW VISION CO

IDT INT'L

SEM HLDGS

NET-A-GO TECH

KAISA GROUP

ARES ASIA

AOM INT'L

TRIO IND ELEC

LING YUI

520690

513120

588860

159615

516500

510660

512290

159506

02268

159859

588250

159316

520880

159849

159992

CMB International has lowered the target price for WUXI XDC to 82 yuan, maintaining a "Buy" rating. It is expected that revenue will grow by 46.7% year-on-year in 2025, with adjusted net profit increasing by 69.9%. As of the end of last year, the backlog of uncompleted orders grew by 50.3% to 1.49 billion USD, and new signed orders increased by 41% to 1.33 billion USD. Management expects revenue growth to exceed 40% in 2026

AASTOCKS

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI XDC

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

CITIC International lowered the target price for WuXi XDC to 82 yuan, rating it as "Buy."

Goldman Sachs released a report stating that WuXi XDC's performance in the second half of last year met expectations, with revenue increasing by 35.9% year-on-year and net profit rising by 26.4% to RMB 735 million. Management's guidance for this year is in line with expectations, forecasting revenue growth of approximately 35% to 40% by 2026. Goldman Sachs has raised its adjusted net profit forecasts for 2026 to 2028 and maintained a "Buy" rating, with a slight decrease in the target price to HKD 85.9

Goldman Sachs slightly lowered the target price for WUXI XDC to 85.9 yuan, with this year's guidance in line with expectations

WUXI XDC rose 10.33%; WuXi AppTec rose 10.13%, with a transaction volume of HKD 1.254 billion; WuXi Biologics rose 4.38%, with a transaction volume of HKD 1.161 billion; Crystal International Holdings rose 1.46%, with a transaction volume of HKD 427 million; Kanglong Chemical rose 4.08%, with a market value of HKD 33.6 billion

HK Stock Movers Tracker

Hong Kong Stock Movement: WUXI XDC's performance shows strong growth of 10.33%, UBS maintains "Buy" rating to support stock price rise

09888

01024

09988

00700

09896

09618

03939

00322

00883

On March 24th, Hong Kong stocks strengthened during the session, with the Hang Seng Index rising by 2.19% and the Hang Seng TECH Index increasing by 1.67%. The internet content and retail sectors performed actively, with heavyweight leaders such as Tencent Holdings and Alibaba driving the market higher. Although there is still pressure at high levels, the bullish momentum continues, with Tencent and Alibaba leading the trading volume

- On March 24, Hong Kong's major stock indices rose amidst a positive sentiment, with the Hang Seng Index gaining 2.19% to 24,915.76 points.  
- The market witnessed upward movements in the internet content and retail sectors, while oil and gas exploration stocks generally declined due to weaker international oil prices.  
- Investors remain cautious despite gains, focusing on Hong Kong's export performance, retail sales data, and currency fluctuations.

Market Heartbeat

BIDU-SW

KUAISHOU-W

BABA-W

TENCENT

MNSO

JD-SW

WANGUO GOLD GP

TINGYI

CNOOC

Krne Csi China Internet

E Fund CSI HK Connect Internet ETF

Amplify Online Retail ETF

Tencent Holdings Limited

Alibaba

SPDR S&P Retail ETF

Global X E-commerce ETF

Tencent

CSOP HS TECH

Hang Seng TECH Index

VanEck Retail ETF

Hwabao CSI HK Equities Internet ETF

ProShares Online Retail

Emerging Markets Internet ETF

Hang Seng Index

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

Hong Kong stock market intraday | Hang Seng Index rises 2.19% to return to 24,900 points, with internet retail leading the gains

03858

06088

As of noon on March 24, the three major indices of the Hong Kong stock market collectively strengthened, with the Hang Seng Index rising by 1.83%, showing impressive performance. The retail sector was supported by improved consumer demand, leading to an overall upward trend, with heavyweight stocks such as Alibaba and Tencent Holdings all rising, boosting market sentiment. Among popular stocks, WuXi AppTec surged over 11%, and Tingyi Holding Corp rose more than 6%. The market was active, but the indices had not yet broken through the recent high

- As of March 24, Hong Kong's stock indices have collectively strengthened, with the Hang Seng Index rising 1.83% to 24,828.86 points.  
- The retail sector saw moderate gains supported by improving consumer demand, while the oil and gas exploration sector performed poorly due to energy price fluctuations.  
- Key stocks included WuXi AppTec, which surged 11.42%, and Master Kong Holdings, which rose 6.74%, reflecting active investment interest in resource stocks.

JIAXIN INTL RES

FIT HON TENG

Hong Kong Stock Market Mid-Review | Hang Seng Index rises 1.83%, retail technology stocks strengthen, Tencent and Alibaba rise

WUXI XDC rose 10.63%; WuXi AppTec rose 8.76%, with a transaction volume reaching HKD 853 million; WuXi Biologics rose 3.40%, with a transaction volume reaching HKD 567 million; Crystal International Holdings rose 0.56%, with a transaction volume reaching HKD 207 million; Kanglong Chemical rose 2.55%, with a market value of HKD 33.1 billion

Hong Kong stock movement: WuXi XDC rises 10.63%, strong performance and strategic expansion bring double benefits, igniting market enthusiasm

WuXi XDC's Profit Climbs in 2025; Shares Jump 7%

marketscreener

WuXi XDC's Profit Climbs in 2025; Shares Jump 7%

09992

01585

On March 24, during Hong Kong stock trading, the three major indices continued their rebound, with the Hang Seng Index up 1.41% and the Hang Seng TECH Index up 0.63%. The internet content and information and retailer sectors led the gains as market risk appetite recovered. Leading stocks such as Tencent Holdings and Alibaba were active, driving a synchronized upward movement in the technology sector, with indices currently trading near their previous highs

- On March 24, Hong Kong stocks showed a bullish trend, with the Hang Seng Index reporting a rise of 1.41% to 24,725.87 points.  
- Key sectors such as technology and retail benefited from improved market sentiment, while oil and gas exploration saw declines due to weakening international oil prices.  
- Investors are currently focused on retail sales, exports, and PMI data, which will influence market perceptions of economic recovery quality.

POP MART

YADEA

ChinaAMC Hang Seng Technology ETF(QDII)

FI2 CSOP HSI

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Dacheng Hang Seng Technology ETF(QDII)

ISHARESHSTECH

FI CSOP HSI

CAM HS TECH

ISHARESHSI

HSTECH ETF

Hang Seng TECH ETF I

China Southern Hang Seng ETF

GX HS TECH

Tianhong Hang Seng TECH ETF(QDII)

FL2 CSOP HSI

Hong Kong Stocks Intraday | Hang Seng Index Rises 1.41% Led by Tech; Tencent Holdings Up 1.93%

UBS lowered the target price for WuXi AppTec to 90.4 yuan, as its performance in the second half of 2022 met expectations, with revenue increasing by 35.9% year-on-year to 3.24 billion yuan, and net profit attributable to shareholders rising by 26.4% to 735 million yuan. It is expected that revenue and adjusted net profit will grow by 46.7% and 69.9%, respectively, by 2025. The company's Singapore facility is expected to commence production in the first half of 2026, maintaining a target of a 30% to 35% compound annual growth rate in revenue from 2025 to 2030. The rating is maintained at "Buy."

UBS lowers the target price of WuXi XDC to 90.4 yuan, with good progress in capacity expansion

WuXi XDC Cayman Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

WuXi XDC Cayman Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

WUXI XDC announced its performance for the fiscal year 2025, with revenue of 5.944 billion RMB (the same below), an increase of 46.7% year-on-year; gross profit of 2.139 billion RMB, up 72.5%. It recorded a net profit of 1.48 billion RMB, a growth of 38.4%, with earnings per share of 1.22 RMB. No final dividend will be distributed

"Performance" WUXI XDC's annual net profit is 1.48 billion RMB, an increase of 38.4%, no dividend declared

WuXi XDC Posts Strong 2025 Profit Growth but Withholds Final Dividend

Tip Ranks

WuXi XDC Posts Strong 2025 Profit Growth but Withholds Final Dividend

01875

Dongyao Pharmaceutical (1875) saw its stock price rise over 16% in the afternoon, reaching HKD 5.25. According to Sing Tao Daily, the company is expected to become a new stock that skyrockets due to a change in ownership. WuXi XDC (2268) has made a voluntary offer to acquire all shares of Dongyao Pharmaceutical, with the transaction expected to be completed in the first half of 2026. Dongyao Pharmaceutical plans to leverage WuXi XDC's brand and platform advantages to advance international operations, enhance production capacity and supply chain resilience, while also increasing R&D investment in CDMO to improve competitiveness. The projected operating revenue for 2025 is expected to be RMB 748 million, a decrease of 32%

Stheadline

BIODLINK-B

Dongyao Pharmaceutical surged 17% in the afternoon, with "Star Market Strategy" first predicting explosive growth potential

JP-WXDC@EC2611A(25507.HK)

JP-WXDC@EC2611A Stock Performance Chart

CITIC International lowered the target price for WuXi XDC to 82 yuan, rating it as "Buy."

Goldman Sachs slightly lowered the target price for WUXI XDC to 85.9 yuan, with this year's guidance in line with expectations

Hong Kong Stock Movement: WUXI XDC's performance shows strong growth of 10.33%, UBS maintains "Buy" rating to support stock price rise

Hong Kong stock market intraday | Hang Seng Index rises 2.19% to return to 24,900 points, with internet retail leading the gains

Hong Kong Stock Market Mid-Review | Hang Seng Index rises 1.83%, retail technology stocks strengthen, Tencent and Alibaba rise